Press Releases
Hogan Lovells represents OptiNose in public offering
12 June 2018
Stephen M. Nicolai
Senior AssociatePhiladelphia
Email stephen.nicolai@hoganlovells.com
Phone +1 267 675 4642
Fax +1 267 675 4600
Practice groupCorporate
Stephen Nicolai uses a practical, business-minded approach to counsel both public and private companies on issues that arise in securities offerings, mergers and acquisitions, securities law compliance, and corporate governance matters.
Stephen has a well-rounded corporate practice and experience with public and private M&A transactions, debt and equity financings, and a broad range of legal matters, including governance, fiduciary duties, and organizational matters. He advises clients across several industries, with a focus and a passion for the life sciences.
Before joining Hogan Lovells, Stephen worked as an associate for another large law firm in Philadelphia, where he advised clients on a range of corporate and securities matters.
Education and admissions
Education
J.D., Villanova University School of Law, magna cum laude, 2011
B.A., West Chester University of Pennsylvania, summa cum laude, 2008
Memberships
Member, American Bar Association
Member, Philadelphia Bar Association
Member, Young Professionals Network of the Greater Philadelphia Chamber of Commerce
Bar admissions and qualifications
Pennsylvania
New Jersey
Representative experience
Represented a clinical-stage pharmaceutical company in its US$80m initial public offering of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.*
Represented a clinical-stage biopharmaceutical company in its US$40m at-the-market equity program led by Cowen and Company.*
Represented a clinical-stage biopharmaceutical company in a US$225m public offering of common stock through a syndicate of underwriters led by J.P. Morgan and Goldman Sachs.*
Regularly advises public companies on a range of corporate governance and securities matters, including fiduciary duties, periodic reports, Section 16 compliance, annual meetings and proxy statements.
Represented a specialty pharmaceutical company in its US$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.
Represented OptiNose, Inc. in its US$120m follow-on public offering of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.
Represented EyePoint Pharmaceuticals, Inc. in its acquisition of Icon Bioscience, Inc. and accompanying US$60m equity financing with a group of third party investors.
Represented a clinical-stage biotechnology company in its US$80m synthetic royalty financing transaction.
Served as internal legal counsel to the interventional vascular unit of a global health care company.
Represented a clinical-stage oncology company in its reverse merger into a Nasdaq-listed public company.
Represented several life companies in at-the-market equity offerings led by Jefferies, Cowen and Company, Cantor Fitzgerald, and B. Riley FBR.
*Matter handled prior to joining Hogan Lovells.
